EUVIMEDEUVIMED entdecken
Crossref

Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome

Daishi Hirano iD, Takuya Fujimaru iD, Mayumi Sako, Seiji Tanaka, Aya Inaba, Toru Uchimura, Koichi Kamei, Takuo Kubota iD, Toshiyuki Ohta, Takayuki Okamoto iD, Hiroshi Tanaka iD, Riku Hamada und 1 weitere

Nephrology Dialysis Transplantation · 28.04.2025 · 40 (5) · 967-977

DOI: 10.1093/ndt/gfae228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 17.10.2024. Verfasst von Daishi Hirano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Agammaglobulinemia, Rituximab, Immunologic Factors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Japanese Society for Pediatric Nephrology, Zenyaku Kogyo Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited data on the long-term outcomes and risk factors for non-recovery after development of rituximab (RTX)-associated persistent hypogammaglobulinaemia among children with idiopathic nephrotic syndrome (NS).

Methods

A nationwide Japanese survey was conducted to determine the prognosis of patients with childhood-onset idiopathic NS who developed persistent hypogammaglobulinaemia after RTX administration. Specifically, predictors of IgG level recovery and risk factors for serious infection were examined.

Results

The cohort comprised 118 patients (66.1% boys; median age at initial RTX administration, 7.5 years). Among the 121 patients diagnosed with persistent hypogammaglobulinaemia, only 31 (26.3%) recovered within a median observation period of 2.8 years; approximately 70% of patients continued to exhibit persistent hypogammaglobulinaemia. Among the patients who recovered from hypogammaglobulinaemia, the median time to recovery was 14.1 months. Patients with a history of steroid-resistant NS were less likely to recover from persistent hypogammaglobulinaemia (hazard ratio 0.28; 95% confidence interval 0.09–0.87). In addition, of the 118 eligible patients, 18 (15.3%) developed serious infections requiring hospitalization, and the main risk factor for infection during hypogammaglobulinaemia was agranulocytosis (a well-known adverse effect of RTX in children).

Conclusions

A significant portion of patients with RTX-associated persistent hypogammaglobulinaemia did not exhibit recovery even after 1 year. Moreover, the data indicate that patients with a history of steroid-resistant NS have a significantly lower probability of recovering from this condition. Agranulocytosis under hypogammaglobulinaemia was significantly associated with an elevated risk of serious infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephrotic SyndromeAgammaglobulinemiaRituximabImmunologic FactorsHumansMaleFemaleChildChild, PreschoolPrognosisFollow-Up StudiesRisk FactorsAdolescentInfantRetrospective StudiesJapan

Stichwörter der Autor:innen

childrenhypogammaglobulinaemianephrotic syndromerecoveryrituximab

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Nephrology, St Luke's International Hospital, Tokyo, Japan.
  • Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics and Child Health, Kurume University Medical Center, Kurume, Japan.
  • Department of Pediatrics, Yokohama City University Medical Center, Yokohama, Japan.
  • Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Daishi Hirano, Takuya Fujimaru, Takuo Kubota, Takayuki Okamoto, Hiroshi Tanaka, Shuichi Ito

Förderung

  • Japanese Society for Pediatric Nephrology
  • Zenyaku Kogyo Co., Ltd.

Zitieren

APA

Hirano, D., Fujimaru, T., Sako, M., Tanaka, S., Inaba, A., Uchimura, T., Kamei, K., Kubota, T., Ohta, T., Okamoto, T., Tanaka, H., Hamada, R., & Ito, S. (2025). Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome. Nephrology Dialysis Transplantation, 40(5), 967-977. https://doi.org/10.1093/ndt/gfae228

Vancouver

Hirano D, Fujimaru T, Sako M, Tanaka S, Inaba A, Uchimura T, et al. Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome. Nephrology Dialysis Transplantation. 2025;40(5):967-977. doi:10.1093/ndt/gfae228

BibTeX
@article{Hirano2025,
  author = {Hirano, Daishi and Fujimaru, Takuya and Sako, Mayumi and Tanaka, Seiji and Inaba, Aya and Uchimura, Toru and Kamei, Koichi and Kubota, Takuo and Ohta, Toshiyuki and Okamoto, Takayuki and Tanaka, Hiroshi and Hamada, Riku and Ito, Shuichi},
  title = {Recovery from rituximab-associated persistent hypogammaglobulinaemia in children with nephrotic syndrome},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {5},
  pages = {967--977},
  doi = {10.1093/ndt/gfae228}
}
Kostenlos starten →